GlassScriptPhysician profile
Runa Shrestha
NPI 1649525866
$4,047.87
in general payments reported to CMS, 2019-2025
40 companies · $48.05 in 2025
The $48.05 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $195 · 2021: $90.00 · 2022: $698 · 2023: $1,382 · 2024: $424 · 2025: $48.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.91 |
| Education | $265.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $607.43 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $439.76 | 2019-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $266.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $256.03 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $225.05 | 2019-2022 | |
| Gilead Sciences, INC. | $199.81 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $187.92 | 2023 | Brukinsa |
| Amgen INC. | $168.94 | 2019-2022 | |
| Kite Pharma, INC. | $151.03 | 2022-2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $145.69 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $129.74 | 2020-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $123.79 | 2020-2024 | Imfinzi, Enhertu, Tagrisso |
| Celgene Corporation | $113.45 | 2019-2023 | Reblozyl |
| Abbvie INC. | $96.64 | 2023-2025 | Venclexta |
| Seagen INC. | $95.94 | 2020-2023 | Tivdak, Adcetris, Tukysa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Runa Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.